HM
Background
CFO with fifteen years building and financing UK oncology and rare-disease biotechs, currently at Selwyn Biotech following CFO seats at Drumlin Therapeutics and Calderwood Therapeutics. I focus on taking pre-clinical and early-clinical companies from seed through Series B, with particular interest in capital strategy,…
Experience20 yrsCompanies6
Career History
Jan 2019 – Dec 20201 yr 11 moChairman at Faraway PharmaLondon, England, United Kingdom
Chair · Target-side M&A
Stepped up to Chair to steward the board through final diligence and completion of the Faraway trade sale.
Feb 2018 – May 20213 yr 3 moChief Financial Officer at Drumlin TherapeuticsLondon, England, United Kingdom
Pre-Seed → Series A4 → 19 FTEs£3M Seed · £22M Series AImmuno-oncology
Led the £22M Series A end-to-end as CFO, taking Drumlin from a four-person spinout to a 19-FTE clinical-stage UK oncology biotech.
Jan 2018 – Present8 yr 6 moChief Financial Officer at Selwyn BiotechLondon, England, United Kingdom
Seed → Series B8 → 34 FTEs£6M Seed · £14M Series A · £31M Series BOncology · Small molecule
Sitting CFO since inception; built finance from scratch and led both the £14M Series A and £31M Series B inside a UK drug-development biotech.
Aug 2017 – Nov 20173 moFinance Director at Larchmont BioLondon, England, United Kingdom
Education
Bachelor's degree — Beckford University (1985–1988)